Patients respond differently to pharmaceutical therapy.
Heart failure comes with complex pathophysiological mechanisms that affect disease progression. In general, these mechanisms stimulate, or are affected by, the neurohormonal millieu and are complicated by systemic co-morbidities. All this impacts how patients – as individuals – respond to pharmacotherapy.
Complicating this issue further is that pharmaceutical agents may work differently from one patient to the next, the benefit of individual drugs within the same class may vary between patients, and patient genetics may also play a role in determining therapy response.
Shape-HF measures changes in patient physiology that define response to therapy. Shape provides early detection of patient response, and helps identify co-morbid physiologies that may influence therapy response. And, Shape-HF testing protocols are flexible across a full range of patient effort, from effort independent testing, to full symptom limited, maximal exercise testing.
Heart failure medications are intended to control renin-angiotensin-aldosterone system activation and neurohormonal response, and their impact on cardiac output, receptor sensitivity and other physiology. Because each of these physiological variables can be measured by Shape-HF, the Shape-HF system offers a sensitive method for quantifying the systemic response to therapy.
Understanding dyspnea is crucial to determining response vs. non-response, but without objective physiological data, such determinations must be made empirically.
The critical information provided by the Shape-HF system helps doctors make informed judgments on therapy response that offer a guide to targeted or more individualized therapy. And, the parameters measured by Shape-HF help uncover co-morbidities that confound therapy response and impact patient prognosis.
Finally, by monitoring patient progress and disease progression, physicians are better able to determine when alternative therapies are indicated.